For more information on any of the following trials, please contact:
Salitah Qureshi, (212) 305-1682

**PRISM-SCARLET (Johnson & Johnson)**
PTG-200 (IL-23)
**IP administration:** Oral
**PI:** Garrett Lawlor
**Disease:** mild/moderate Crohn’s Disease
**Inclusion criteria:** endoscopically and clinically active CD, failed biologics, corticosteroids, immunomodulators.
**Status:** Enrolling

**M16-067 (AbbVie)**
**Risankizumab (IL-23)**
**IP administration:** IV and Subcutaneous injection
**PI:** Garrett Lawlor
**Disease:** moderate/severe ulcerative colitis
**Inclusion criteria:** endoscopically and clinically moderate/severely active UC. Must have failed a biologic
**Exclusion criteria:** previous Stelara use
**Status:** Enrolling

**ADMIRE CD-II (Tigenix)**
**Cx601 (adult allogenic expanded adipose derived Stem Cells)**
**IP administration:** injection under anesthesia
**PI:** Garrett Lawlor
**Disease:** Complex Fistula(s) due to Crohn’s Disease
**Inclusion criteria:** Complex perianal fistula(s); clinically controlled nonactive/ mildly active Crohn’s Disease; failed treatment of fistula with immunosuppressant or biologics
**Exclusion Criteria:** actively draining Simple subcutaneous fistula
**Status:** Enrolling

**M20-259 (AbbVie)**
**Risankizumab vs Ustekinumab**
**IP administration:** IV and Subcutaneous injection
**PI:** Garrett Lawlor
**Disease:** moderate/severe Crohn’s Disease
**Inclusion criteria:** endoscopically and clinically active CD, anti-TNF therapy
**Exclusion criteria:** previous Stelara, natalizumab, vedolizumba and risankizumab use
**Status:** Enrolling

**PRECIOUS**
**Predicting Crohn’s and Colitis Outcomes in the US**
**PI:** Garrett Lawlor
**Disease:** Crohn’s Disease or Ulcerative Colitis
Inclusion criteria: Active ulcerative colitis/Crohn’s Disease; not currently receiving systemic therapy with steroids, immunomodulators or biologics
Exclusion criteria: receive biologics as a first line therapy
Status: Enrolling

SAPPHIRE
Safety of Immunosuppression in a Prospective Cohort of IBD with a History of Cancer
PI: Garrett Lawlor
Disease: Ulcerative colitis or Crohn’s Disease
Inclusion criteria: 1st cancer diagnosis within the last 5 years
Exclusion criteria: chemotherapy/ radiation treatment at enrollment
Status: Enrolling

UPCOMING TRIALS

IM011023 (Bristol Meyer Squibb)
BMS-986165 (Tyrosine Kinase 2 inhibitor)
IP administration: Oral
PI: Garrett Lawlor
Disease: moderate/ severe Crohn’s Disease
Inclusion criteria: endoscopically and clinically active CD; failed any medication.
Exclusion criteria: previous Stelara use

TAK-018 (Takeda)
TAK-018
IP administration: Oral
PI: Bo Shen
Disease: Prevention of postoperative Crohn’s Disease recurrence
Inclusion criteria: planned laparoscopic ileocecal resection with primary anastomosis; postop discontinuation of all medication for CD treatment
Exclusion criteria: More than 3 previous CD surgical procedures; small bowel resection that exceeds 100 cm

KFAH (Eli Lilly)
LY3471851 (IL-2)
IP Administration: Subcutaneous injection
PI: Garrett Lawlor
Disease: Moderate/ Severe Ulcerative Colitis
Inclusion criteria: failed corticosteroids, immunomodulators; bio-naïve

LUCENT (Eli Lilly)
Mirikizumab (IL-23) vs. Vedolizumab
IP administration: IV and Subcutaneous injection
PI: Garrett Lawlor
Disease: Moderate/ Severe Ulcerative Colitis
Inclusion criteria: failed any medication
Exclusion criteria: previous vedolizumab, stelara use